FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB	APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Sullivan John F				2. Issuer Name and Ticker or Trading Symbol TransMedics Group, Inc. [TMDX]							ationship of Reporting Person(s) to Is: (all applicable) Director 10%		suer Owner		
	Last) (First) (Middle) C/O TRANSMEDICS GROUP, INC. ON MINUTEMAN ROAD			3. Date of Earliest Transaction (Month/Day/Year) 05/06/2019							Officer (give title below) VP of Quality	Other below) * & Engineerin	(specify		
(Street) ANDOVER	MA	01810	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Indiv	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)	n-Derivati	vative Securities Acquired, Disposed of, or Benefici						ficially C	hwned				
1. Title of Security (Instr. 3) 2. Tran			2. Transaction	ion //Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (1 8)	ction	4. Securities Acquired (A) on Disposed Of (D) (Instr. 3, 4		A) or	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
						Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)		
Common Stock			05/06/20	019		J ⁽¹⁾		33,000	D	(1)	0	D			
Common Stock 05			05/06/20	019		J ⁽¹⁾		9,428	A	(1)	9,428	D			
		Table II -	Derivative	e Sec	urities Acqui	red. D	isno	sed of, or	Renefic	rially Ov	ned				

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/\	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Security			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)	(i) (ilisu: 4)	
Stock Option (Right to Buy)	\$16.5 ⁽²⁾	05/06/2019		J (2)			1,000 ⁽²⁾	(3)	12/16/2020	Common Stock	285	(2)	0	D	
Stock Option (Right to Buy)	\$57.75 ⁽²⁾	05/06/2019		J ⁽²⁾		285 ⁽²⁾		(3)	12/16/2020	Common Stock	285	(2)	285	D	
Stock Option (Right to Buy)	\$0.11 ⁽²⁾	05/06/2019		J ⁽²⁾			51,162 ⁽²⁾	(3)	09/27/2021	Common Stock	14,617	(2)	0	D	
Stock Option (Right to Buy)	\$0.39 ⁽²⁾	05/06/2019		J ⁽²⁾		14,617 ⁽²⁾		(3)	09/27/2021	Common Stock	14,617	(2)	14,617	D	
Stock Option (Right to Buy)	\$0.08 ⁽²⁾	05/06/2019		J ⁽²⁾			35,000 ⁽²⁾	(3)	03/27/2023	Common Stock	10,000	(2)	0	D	
Stock Option (Right to Buy)	\$0.28 ⁽²⁾	05/06/2019		J ⁽²⁾		10,000 ⁽²⁾		(3)	03/27/2023	Common Stock	10,000	(2)	10,000	D	
Stock Option (Right to Buy)	\$0.08 ⁽²⁾	05/06/2019		J ⁽²⁾			66,402 ⁽²⁾	(3)	05/29/2023	Common Stock	18,972	(2)	0	D	
Stock Option (Right to Buy)	\$0.28 ⁽²⁾	05/06/2019		J ⁽²⁾		18,972 ⁽²⁾		(3)	05/29/2023	Common Stock	18,972	(2)	18,972	D	
Stock Option (Right to Buy)	\$0.63 ⁽²⁾	05/06/2019		J ⁽²⁾			85,530 ⁽²⁾	(4)	06/22/2027	Common Stock	24,437	(2)	0	D	
Stock Option (Right to Buy)	\$2.21 ⁽²⁾	05/06/2019		J ⁽²⁾		24,437 ⁽²⁾		(4)	06/22/2027	Common Stock	24,437	(2)	24,437	D	

Explanation of Responses:

^{1.} The Common Stock reported herein as being disposed of is common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), such common stock of TransMedics, Inc. was converted into shares of common stock of the Issuer on a 3.5-for-one basis.

^{2.} The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the

Merger Agreement, each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price.

3. The option is fully vested.

4. The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, June 22, 2017.

Remarks:

By: /s/ Stephen Gordon, Attorney-in-Fact 05/06/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.